Observation On The Efficacy Of Yangfei Yiqi Decoction Combined With Osimertinib In The Treatment Of Advanced Non-small Cell Lung Cancer With Qi And Yin Deficiency Syndrom

Objective:This study aimed to observe the therapeutic effect of traditional Chinese medicine combined with Osimertinib in the treatment of advanced non-small cell lung cancer,it can provide reference for clinical treatment and clinical research.Methods:56 advanced NSCLC patients with EGFR mutations were randomly divided into two groups.The treatment group used Yangfei Yiqi Decoction with Osimertinib,and the control group used Osimertinib single drug.The main outcome measures were short-term effects,TCM(Traditional Chinese Medicine)syndrome score,tumor marker,tumor response and incidence of adverse reactions.Useing IBM SPSS 25.0 to statistical analysis.Results:56 cases were enrolled in this study.In the comparison of short-term effects:DCR in treatment group and control group is 96.42% vs 92.85%,ORR is75%vs64.28%,with no statistical difference(P>0.05).Compared with tumor markers CEA and CA125,CEA decreased by 189.78(ng/ml)vs 116.99(ng/ml)in the treatment group and control group,CA125 decreased by 123.28(U/ml)vs 90.08(U/ml)respectively,in each group,with no statistical difference(P>0.05).The effective rate of TCM syndrome score in the treatment group and control groupwas is 82.14% vs39.29%(P < 0.05).There was significant difference between the two groups in the symptoms of dry mouth and tongue,shortness of breath and fatigue(P < 0.01);The KPS score decreased by 13.57 in the treatment group and 7.50 in the control group,with no statistical difference(P>0.05);The incidence of adverse reaction were39.29% and 53.57%,with no statistical difference(P>0.05).Conclusion:Yangfei Yiqi Decoction with targeted drug has more advantages in the reducing adverse drug reactions,improve clinical symptoms and TCM syndrome,relief patients’ pain,improve their survival quality and physical situation.